Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.
All Keywords
【저자키워드】 COVID-19, vaccination, multiple sclerosis, Humoral immunity, Ocrelizumab, B-cell, 【초록키워드】 Efficacy, Vaccine, COVID-19 vaccine, therapy, COVID-19 pandemic, Infection, B cell, vaccine response, management, Patient, patients, COVID-19 mRNA vaccine, immunosuppressive therapies, Relapsing-Remitting Multiple Sclerosis, offer, IMPROVE, receiving, depleting, 【제목키워드】 failure, Multiple, sclerosis,
【저자키워드】 COVID-19, vaccination, multiple sclerosis, Humoral immunity, Ocrelizumab, B-cell, 【초록키워드】 Efficacy, Vaccine, COVID-19 vaccine, therapy, COVID-19 pandemic, Infection, B cell, vaccine response, management, Patient, patients, COVID-19 mRNA vaccine, immunosuppressive therapies, Relapsing-Remitting Multiple Sclerosis, offer, IMPROVE, receiving, depleting, 【제목키워드】 failure, Multiple, sclerosis,